Interviews

Jorge Nieva, MD, reviews long-term taletrectinib data in ROS1+ non–small cell lung cancer, including about 90% response rates across fusion partners and manageable safety.

Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.

Andrew Kuykendall, MD, discusses where rusfertide may fit in polycythemia vera, from replacing phlebotomy to use with cytoreductive therapy and fatigue.

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.

Daniel DeAngelo, MD, PhD, discusses how TKIs have given patients with CML a full lifespan and what is being done to build on the incredible progress in this setting.

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a chronic condition at IMS 2026.

Andrew Kuykendall, MD, reviews VERIFY trial that led to FDA approval of rusfertide in polycythemia vera.

Saad Usmani, MD, discusses how MRD negativity may define treatment duration and raise cure fractions in multiple myeloma, live from IMS.

Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted triplet therapies.

At the 2026 IMS meeting, Sagar Lonial, MD, discusses the FDA approval of iberdomide, early enthusiasm for its use, and the CELMoD trials clinicians should watch.

Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.

As Leukemia and Lymphoma Awareness Month draws to a close, Daniel DeAngelo, MD, PhD, discusses the key trends in acute lymphoblastic leukemia treatment.

Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.

Pieter Sonneveld, MD, PhD, discusses CAR T-cell therapy and bispecific antibodies moving to frontline myeloma care.

Trispecific T-cell engagers target 2 tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.

Jeffrey V. Matous, MD, discusses moving fixed-duration T-cell–redirecting therapy into frontline multiple myeloma treatment and the persistent challenge of ultra-high-risk disease.

Luciano Costa, MD, of UAB, explains why most patients with myeloma will soon need just 1 or 2 lines of therapy to restore normal life expectancy.

C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.

In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.

Peter Voorhees, MD, discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at the IMS conference.

Geoffrey Y. Ku, MD, discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.

Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG cure criteria for myeloma and the meaning of durable CAR-T responses in these patients.

Gurbakhash Kaur, MD, discusses how quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping the role of autologous transplant in multiple myeloma.

New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.

Shubham Pant, MD, discusses the expanding pipeline of RAS-directed agents beyond daraxonrasib for patients with pancreatic cancer.

Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.

For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.

David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.

Jonathan Villena-Vargas, MD, explains how a team-based training model makes subcostal robotic lung surgery safe, even in complex neoadjuvant cases.

Jeff Sharman, MD, explores how targeted therapies have transformed CLL treatment and what emerging approaches could shape the future of care.